TY - JOUR
T1 - Impact of mutational status on survival in low-grade serous carcinoma of the ovary or peritoneum
AU - Gershenson, David M.
AU - Sun, Charlotte C.
AU - Wong, Kwong Kwok
N1 - Funding Information:
Funding: This work was supported in part by The National Cancer Institute at the National Institutes of Health (P50 CA83639 to DMG and KKW), National Institutes of Health through Cancer Center Support Grant (P30 CA016672 to DMG, CCS, and KKW), and The Sara Brown Musselman Fund for Serous Ovarian Cancer Research (DMG, CCS, and KKW).
Publisher Copyright:
© 2015 Cancer Research UK. All rights reserved.
PY - 2015/11/3
Y1 - 2015/11/3
N2 - Background:Low-grade serous carcinoma of the ovary or peritoneum is a distinct, well- recognized histologic subtype characterized by young age at diagnosis, relative chemoresistance, and prolonged overall survival. Common mutations reported to be found within this subtype include KRAS and BRAF.Methods:Using clinical information of patients from our IRB-approved registry and tissue from a subset of these patients, we performed mutational analysis for KRAS and BRAF using the direct Sanger sequencing technique and correlated findings with the clinical outcome, overall survival (OS).Results:In 79 cases, patients with KRAS or BRAF mutations (n=21) had a significantly better OS than those with wild-type KRAS or BRAF (n=58) (106.7 months (95% CI, 50.6, 162.9) vs 66.8 months (95% CI, 43.6, 90.0)), respectively (P=0.018).Conclusions:Mutational status appears to be a potential prognostic factor in low-grade serous carcinoma of the ovary or peritoneum.
AB - Background:Low-grade serous carcinoma of the ovary or peritoneum is a distinct, well- recognized histologic subtype characterized by young age at diagnosis, relative chemoresistance, and prolonged overall survival. Common mutations reported to be found within this subtype include KRAS and BRAF.Methods:Using clinical information of patients from our IRB-approved registry and tissue from a subset of these patients, we performed mutational analysis for KRAS and BRAF using the direct Sanger sequencing technique and correlated findings with the clinical outcome, overall survival (OS).Results:In 79 cases, patients with KRAS or BRAF mutations (n=21) had a significantly better OS than those with wild-type KRAS or BRAF (n=58) (106.7 months (95% CI, 50.6, 162.9) vs 66.8 months (95% CI, 43.6, 90.0)), respectively (P=0.018).Conclusions:Mutational status appears to be a potential prognostic factor in low-grade serous carcinoma of the ovary or peritoneum.
UR - http://www.scopus.com/inward/record.url?scp=84946490061&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946490061&partnerID=8YFLogxK
U2 - 10.1038/bjc.2015.364
DO - 10.1038/bjc.2015.364
M3 - Article
C2 - 26484411
AN - SCOPUS:84946490061
SN - 0007-0920
VL - 113
SP - 1254
EP - 1258
JO - British journal of cancer
JF - British journal of cancer
IS - 9
ER -